<DOC>
	<DOCNO>NCT02475109</DOCNO>
	<brief_summary>The objective study assess safety tolerability topical ocular PAN-90806 patient proliferative diabetic retinopathy .</brief_summary>
	<brief_title>Study Topical Ocular PAN-90806 PDR</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Aged 18 year old type 1 type 2 diabetes Proliferative diabetic retinopathy ( PDR ) study eye retina without diabetic macular edema ( DME ) involve center macula Demonstrate ability , family member willing able , instill topical ocular drop study eye Current recent use ( within last 3 month ) antivascular endothelial growth factor ( antiVEGF ) either eye ; Uncontrolled hypertension despite use antihypertensive medication Unwillingness refrain wear contact lenses duration study . Participation investigational drug device study , systemic ocular , within past 3 month Women pregnant nursing Known serious allergy hypersensitivity fluorescein dye use angiography component PAN90806 formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
</DOC>